Naturopathy, Acupuncture, Homeopathy, Nutrition, Herbal Medicine , Fluoride Removal Water Filters

Online Naturopathic Health Resource

This store is powered by Ecwid - E-Commerce Software. If your browser does not support JavaScript, please proceed to its simple HTML version.

Effect of (Avandia) rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes

Rosiglitazone (Avandia) is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

See also Natural Alternatives to the Antidiabetic Drug Avandia

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.

Nissen SE, Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21.

enfrdeitptrues
05658833
TodayToday709
YesterdayYesterday2400
This_WeekThis_Week5403
This_MonthThis_Month56162